Enger Tone B, Pleym Hilde, Stenseth Roar, Greiff Guri, Wahba Alexander, Videm Vibeke
Department of Laboratory Medicine, Children's and Women's Health, Faculty of Medicine, NTNU-Norwegian University of Science and Technology, Trondheim, Norway; Department of Cardiothoracic Anesthesia and Intensive Care, St. Olavs University Hospital, Trondheim, Norway.
Department of Circulation and Medical Imaging, Faculty of Medicine, NTNU-Norwegian University of Science and Technology, Trondheim, Norway; Clinic of Anesthesia and Intensive Care, St. Olavs University Hospital, Trondheim, Norway.
J Cardiothorac Vasc Anesth. 2017 Jun;31(3):837-846. doi: 10.1053/j.jvca.2016.10.005. Epub 2016 Oct 11.
To investigate whether a multimarker strategy combining preoperative biomarkers representing distinct pathophysiologic pathways enhances preoperative risk assessment of acute kidney injury after cardiac surgery (CSA-AKI) and increases knowledge of underlying pathogenesis.
Prospective, cohort study.
Single-center tertiary referral hospital.
The study comprised 1,015 adults undergoing cardiac surgery with cardiopulmonary bypass.
CSA-AKI was defined as≥50% increase in serum creatinine concentration, absolute increase≥26 µmol/L, or new requirement for dialysis. Preoperative and perioperative information until hospital discharge was recorded. Preoperative plasma levels of C-reactive protein, terminal complement complex, neopterin, lactoferrin, N-terminal pro-brain natriuretic peptide, and cystatin C were determined using enzyme immunoassays. Biomarkers were selected based on causal hypotheses of underlying mechanisms and were related to inflammatory, hemodynamic, or renal signaling pathways.
One hundred patients (9.9%) developed CSA-AKI. Higher baseline plasma concentrations of neopterin and N-terminal pro-brain natriuretic peptide were associated independently with CSA-AKI (p = 0.04 and p<0.001, respectively). Lower baseline plasma lactoferrin concentrations were observed in patients with CSA-AKI (p = 0.05). Compared with clinical risk assessment, addition of these biomarkers provided a slight, but significant, increment in predictive utility (area under the curve 0.81-0.83, likelihood ratio test p<0.001). A net of 12% of patients were reclassified correctly, and improved prediction was demonstrated, especially in patients with intermediate risk (56% correct reclassification).
Preoperative hemodynamic, renal, and immunologic function play central roles in the pathogenesis of CSA-AKI. These findings add evidence to the potential of a multimarker approach to improve preoperative prediction of CSA-AKI.
探讨一种结合代表不同病理生理途径的术前生物标志物的多标志物策略是否能增强心脏手术后急性肾损伤(CSA-AKI)的术前风险评估,并增加对潜在发病机制的认识。
前瞻性队列研究。
单中心三级转诊医院。
该研究包括1015例接受体外循环心脏手术的成年人。
CSA-AKI定义为血清肌酐浓度升高≥50%、绝对升高≥26µmol/L或新的透析需求。记录术前和围手术期直至出院的信息。使用酶免疫测定法测定术前血浆中C反应蛋白、末端补体复合物、新蝶呤、乳铁蛋白、N末端脑钠肽前体和胱抑素C的水平。基于潜在机制的因果假设选择生物标志物,这些生物标志物与炎症、血流动力学或肾脏信号通路相关。
100例患者(9.9%)发生CSA-AKI。新蝶呤和N末端脑钠肽前体的基线血浆浓度较高分别独立与CSA-AKI相关(p分别为0.04和p<0.001)。CSA-AKI患者的基线血浆乳铁蛋白浓度较低(p=0.05)。与临床风险评估相比,添加这些生物标志物在预测效用方面有轻微但显著的增加(曲线下面积为0.81-0.83,似然比检验p<0.001)。总计12%的患者被正确重新分类,并且显示出预测改善,尤其是在中度风险患者中(56%正确重新分类)。
术前血流动力学、肾脏和免疫功能在CSA-AKI的发病机制中起核心作用。这些发现为多标志物方法改善CSA-AKI术前预测的潜力提供了证据。